Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE | P22303 | 14/20 | 0.36 |
| ▸ | DRD2 | P14416 | 2/20 | 0.34 |
| ▸ | DRD3 | P35462 | 2/20 | 0.34 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | TAOK1 | Q7L7X3 | 2/20 | 0.32 |
| ▸ | TAOK3 | Q9H2K8 | 2/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | THRA | P10827 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27367100 | 0.83 | MCHR1 (0.38) | ACHEDRD2DRD3MCHR1TAOK1 | |
| SCHEMBL27367338 | 0.77 | ACHE (0.32) | ACHEDRD2DRD3 | |
| SCHEMBL27366761 | 0.74 | LMNA (0.32) | DRD2DRD3MCHR1 | |
| SCHEMBL27367345 | 0.67 | PDK1 (0.38) | — | |
| SCHEMBL27367322 | 0.66 | CCKBR (0.35) | MCHR1 | |
| SCHEMBL27367125 | 0.64 | MCHR1 (0.39) | ACHEDRD2DRD3MCHR1CA1 | |
| SCHEMBL27367058 | 0.63 | MCHR1 (0.39) | ACHEDRD2DRD3MCHR1TAOK1 | |
| SCHEMBL27367022 | 0.63 | HTR2C (0.45) | ACHEMCHR1CA1CA2THRB | |
| SCHEMBL13350380 | 0.61 | ESR1 (0.49) | DRD2DRD3 | |
| SCHEMBL15866398 | 0.60 | ESR1 (0.47) | DRD2DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024049929-A2 | PANNEXIN-1 MODULATORS AND METHODS OF TREATING DISORDERS IN WHICH PANNEXIN-1 IS IMPLICATED | PANNEX THERAPEUTICS INC. (US) | 2024-03-07 | — | — | WO | disclosed |